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Deleterious effects of dopamine (DA) involving mitochondrial dysfunction have an important role in DA-associated neuronal disorders,
including schizophrenia and Parkinson's disease. DA detrimental effects have been attributed to its ability to be auto-oxidized to toxic reactive
oxygen species. Since, unlike Parkinson's disease, schizophrenia does not involve neurodegenerative processes, we suggest a novel mechanism by
which DA impairs mitochondrial function without affecting cell viability. DA significantly dissipated mitochondrial membrane potential (Δψm) in
SH-SY5Y cells. Bypassing complex I prevented the DA-induced depolarization. Moreover, DA inhibited complex I but not complex II activity in
disrupted mitochondria, suggesting complex I participation in DA-induced mitochondrial dysfunction. We further demonstrated that intact
mitochondria can accumulate DA in a saturated manner, with an apparent Km=122.1±28.6 nM and Vmax=1.41±0.15 pmol/mg protein/min,
thereby enabling the interaction between DA and complex I. DA accumulation was an energy and Na+-dependent process. The pharmacological
profile of mitochondrial DA uptake differed from that of other characterized DA transporters. Finally, relevance to schizophrenia is demonstrated
by an abnormal interaction between DA and complex I in schizophrenic patients. These results suggest a non-lethal interaction between DA and
mitochondria possibly via complex I, which can better explain DA-related pathological processes observed in non-degenerative disorders, such as
schizophrenia.
© 2007 Elsevier B.V. All rights reserved.Keywords: Dopamine; Mitochondria; Mitochondrial membrane potential; Complex I; Mitochondrial dopamine uptake; Schizophrenia1. Introduction
Dysregulation of dopamine (DA) homeostasis has been
suggested to play an important role in the pathophysiology of
several psychiatric and neurological disorders such as schizo-
phrenia and Parkinson's disease. In neurodegenerative disorder
the degeneration of catecholaminergic neuron has been
attributed to increased cytosolic levels of DA and its oxidized
metabolites [1–5]. In schizophrenia, however, DA increased
level [6,7], is not associated with neuronal death. The mech-⁎ Corresponding author. Laboratory of Psychobiology, Department of
Psychiatry, Rambam Medical Center and B. Rappaport Faculty of Medicine,
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doi:10.1016/j.bbabio.2007.10.006anism by which DA exerts its toxic effects in vivo is still
unclear, yet several processes have been suggested, including
the induction of a state of oxidative stress [8,9], apoptosis [10–
12] as well as interference with mitochondrial respiration.
Mitochondria are responsible for many essential processes
including energy production, intracellular calcium buffering,
neurotransmitter transmission, apoptosis and ROS production,
all leading either to cell death or playing a role in synaptic
plasticity such as structural remodeling and long term functional
changes [13,14]. Indeed, impaired mitochondrial function and
the inability to maintain cellular ATP levels have been suggested
as a possible cause for pathological processes in DA-related non-
degenerative disorders such as schizophrenia as well as in
neurodegenerative diseases such as Parkinson's [15–21].
Accumulating experimental evidence suggests that DA can
inhibit the mitochondrial respiratory system. Thus, elevated rat
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DOPA or D-methamphetamine resulted in a reduction of the
activity of the first complex of the respiratory system (complex
I) and ATP levels in the striatum [22,23]. In a neuronal cell line
DA induced a reduction in cellular ATP levels without affecting
cell viability [24]. In isolated intact rat brain mitochondria DA
inhibited ATP coupled state III respiration [25] and suppressed
pyruvate- and succinate-dependent electron transport [26]. In
disrupted mitochondria from both rat brain and human platelets
DA reversibly inhibited complex I activity but not that of
complexes IV of the respiratory system and of ATPase/ATP
synthase (complex V) [27,28]. Two mechanisms have been
suggested for DA interference with mitochondrial respiration.
The first, involves DA enzymatic catabolism or autooxidation
to highly reactive oxygen species (ROS), and has been sug-
gested to underlie cell death in Parkinson's disease. The second
mechanism, involves a direct reversible inhibition of complex I
activity, which can disrupt mitochondrial activity leading to
abnormal neuronal transmission, rather than cell death, as is
observed in schizophrenia [24]. Indeed, studies focusing on the
mitochondrial respiratory system in schizophrenia have
revealed brain region specific alterations in the activities of
complexes I–III, II and IV [19,29,30]. Complex I activity was
also altered in platelets and lymphocytes of schizophrenic
patients in a disease specific and state dependent manner [16].
In addition, abnormal expression of mitochondrial genes in
general, and of nuclear encoded genes of complex I, in par-
ticular, was also observed both in brain and in the periphery of
schizophrenic patients [15–18,20,31].
The aforementioned findings suggest that the interaction
between DA and complex I can play an important role in the
pathophysiology of non-degenerative disorders such as schizo-
phrenia. In order to verify such an interaction between DA and
mitochondria, we investigated the ability of DA to enter the
mitochondria and disrupt mitochondrial function via its inter-
action with complex I in viable cells. The results of the present
study demonstrate that in intact cells DA causes dissipation of
mitochondrial membrane potential (Δψm) possibly via its
interaction with complex I. Moreover, the results demonstrate
that intact mitochondria can accumulate DA through their
highly selective inner membrane, enabling its interaction with
complex I. The kinetics and pharmacological profile of this
process were characterized. Finally, a schizophrenia-specific
pathological interaction between DA and complex I is dem-
onstrated in mitochondria isolated from platelets of patients and
healthy controls suggesting that this interaction may be of
relevance for schizophrenia.
2. Materials and methods
2.1. Cell treatment
1×106 human neuroblastoma SH-SY5Y cells were plated in DMEM
supplemented with 10% fetal calf serum, L-glutamine and antibiotics at 37 °C in a
5% CO2 humidified incubator. Following 24 h, the medium was replaced with
serum free DMEM for an additional 18–20 h. Prior to treatment, cells were
preincubated with 0.1 mM tranylcypromine (MAOA and B inhibitor) for 30 min.
Cell viability was determined by Trypan Blue. Protein concentration was
determined by Bradford reagent.2.2. Imaging mitochondrial membrane potential
2.2.1. Confocal microscopy
Mitochondrial membrane potential (Δψm) was assessed with 5,5′,6,6′-
tetrachloro-1,1′,3,3′-tetraethylbenzimidazolocarbocyanine iodide (JC-1)
[32,33]. The positively charged JC-1 is specific for mitochondrial membrane
potential and its color alters reversibly from green (J-monomer, at low JC-1
concentration) to red (J-aggregates, at high JC-1 concentration) with increased
mitochondrial membrane potential. For confocal microscopy cells were loaded
for 15 min with 5 μM JC-1 in HBSS (HEPES buffered salt solution containing:
137 mM NaCl, 5 mM KCl, 0.9 mM MgSO4, 1.4 mM CaCl2, 10 mM NaHCO3,
0.6 mM Na2HPO4, 0.4 mM KH2PO4, 5.6 mM glucose and 20 mM HEPES pH
7.4) at 37 °C. Cells were washed twice with HBSS and incubated for additional
30 min. Images were acquired, before and 1–10 min after the addition of 10−4 M
DA, by a Radiance 2001 laser scanning confocal imaging system (Nikon Eclipse
E600). A 488-nm excitation from an argon laser was used in conjunction with a
510 nm dichroic mirror. Emitted light was further separated by a 575 nm
dichroic mirror before being filtered at 530±10 nm and 590±17 nm, the
wavelengths corresponding to the peak fluorescence from the monomer and
aggregate signals, respectively. The ratio of fluorescence emission 590:530 nm
was used as an indicator of Δψm [32,33]. Data analysis was performed using
Image Pro Plus MediaCybernetics software.
2.2.2. Flow cytometry
Suspended cells (106 cells/ml of HBSS or PBS) were pretreated with different
drugs before the incubation with JC-1 at 37 °C as follows: 5 μM of the uncoupler
carbonyl cyanide m-chlorophenylhydrazine (CCCP), 0.001–10 μM of complex I
inhibitor, rotenone or 5×10−5 to 10−4 M DA for 5 min. Since a significant
dissipation of Δψm was already observed with 1 μM rotenone this concentration
was used throughout the study. For succinate induced respiration, 5 mM succinate
was added to cells immediately before treatment. Cells were washed twice at room
temperature and analyzed by FACS Calibur (BECTON DICKINSON, USA)
equipped with a single argon ion laser. Samples were excited at 488 nm and the
ratio of fluorescence emission at 590:530 (red: green) was determined as an
indicator of mitochondrial membrane potential [34]. A minimum of 10,000 events
per sample were analyzed, using the “Cell Quest” software.
2.3. Intracellular DA
Intracellular DA was measured by HPLC with an electrochemical detector
(ESA Inc. MA, USA). Cells were incubated as specified for the JC-1 reaction in
the presence or absence of three different concentrations of DA (5×10−5 to
5×10−4) and of 5 mM succinate. The reaction was terminated by centrifugation
at 280×g at room temperature for 15 min. The pellet was washed three times
with 100 times excess of buffer and centrifuged between each wash. The final
pellet was placed on ice and dissolved in 100 μl of 0.1 M HClO4. After freezing
and thawing the homogenate was centrifuged at 12,000×g at 4 °C, and aliquots
of the supernatant were analyzed with HPLC. The electrodetection was
performed at +0.3 V. The mobile phase contained 0.1 M NaH2PO4, 0.27 mM
Na2EDTA, 1 mM octanesulfuric acid, 4.5% acetonitrile, 2.5% methanol
(pH=2.75). Data were analyzed using Borwin software [35].
2.4. Reactive oxygen species (ROS) production
The formation of intracellular ROS was measured by incubating SH-SY5Y
cells (2×105 cells) suspended in HBSS in the presence of 5-(and-6)-carboxy-2′,7′-
dichlorodihydrofluorescein diacetate (H2DCFDA, Molecular Probes) (final
concentration 25 μM) for 30 min at 37 °C [36]. H2DCFDA is a stable non-
fluorescent molecule that passively diffuses into cells, where the acetate can be
cleaved by intracellular esterases to produce a polar diol that is well retained within
the cells. The diol can then be oxidized by ROS to a fluorescent form. Redox state
of cells was determined by exciting H2DCFDA-loaded cells at 485 nm and
detection of emitted fluorescence was performed at 520 nm using FLUOstar
OPTIMA (BMG Labtech, Germany). After loading, DA (10−6 and 10−4 M) was
added to the cells at different concentrations and measurements were obtained
every 5 min for up to 30 min. H2O2 (10
−4 M) was used as a positive control.
Superoxide formation was measured by incubating SH-SY5Y cells (2×105
cells) suspended in HBSS using Red mitochondrial superoxide indicator
Table 1
Clinical data for the different groups
Controls Schizophrenic patients Depressed patients
Medicated Unmedicated MDD BD
No. of patients 24 25 25 17 10
Gender (F/M) 13 / 11 10 / 15 14 / 11 11/6 6/4
Age±SD 35.0±9.8 25.9±7.0 32.0±13.0 53.0±14.0a 50.0±13.5b
(range) (22–50) (18–43) (18–60) (33–75) (27–75)
Duration of
illness
5.2±5.5 4.2±10.0 10.3±10.3 18.0±11.1c
(range) (0.5–20) (0.5–20) (0.5–34) (2–41)
A significant difference for age and duration of illness was demonstrated in
depressed patients as compared with the schizophrenic or control groups, which
did not differ from each other. The significance of the difference (df=100
F=19.291 pb0.0001 for age of subjects; df=76 F=6.720 p=0.0005 for
duration of illness) was analyzed by one way ANOVA followed by Bonferroni.
apb0.001(t=5.033); bpb0.01 (t=3.533)vs. control, cpb0.01(t=5.367) vs.
schizophrenic patients.
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[37]. Superoxides were determined by exciting MitoSOX-loaded cells at 485 nm
and detection of emitted fluorescence was performed at 580 nm using FLUOstar
OPTIMA (BMG Labtech, Germany). After loading, DA (10−6, 10−4 M) were
added to the cells at different concentrations and measurements were obtained
every 5 min for up to 30 min. Rotenone (10 μM) was used as a positive control.
2.5. Preparation of synaptosome-free mitochondria from rat brain
Brain mitochondria were isolated from male Sprague–Dawley rats (300–
350 g) as previously described [38]. In short, rats were sacrificed by decapitation,
their brains rapidly removed, washed, minced and homogenized by Dounce
homogenizer in ice cold 10 mM Tris–HCl buffer (pH 7.4) containing 0.25 M
sucrose 1 mMEDTA and defatted BSA (3%w/v). Single brain homogenates were
brought to 25 ml and centrifuged at 1000×g for 10 min. The supernatant was
collected and centrifuged at 12,000×g for 10 min. The pellet was gently suspended
and recentrifuged with the same buffer lacking EDTA and BSA. The pellet was
further purified on discontinuous Percoll gradient to remove synaptosomes [38].
The mitochondria containing layer was diluted 1:10 in isolation buffer and centri-
fuged at 12000×g for 10 min. The final pellet was immediately used for uptake
experiments. Mitochondrial protein yields were 8–12 mg per rat brain. All animal
procedures were approved by the Technion Animal Care and Use Committee.
Purity and integrity of mitochondria, isolated by Percoll and thoroughly
washed, were studied by electron microscopy as described previously [38] and
by evaluating respiratory control rates in the presence of ADP (state 3 respiration
rates) that was determined polarographically with a thermostatically controlled
Clark oxygen electrode (Strathkelvin Instruments LTD Glasgow, Scotland) [39].
2.6. Mitochondrial swelling
Ca2+ induced mitochondrial swelling was determined spectrophotometri-
cally (Milton Roy Spectronic Genesis 5, Rochester, NY, USA) at 25 °C as
previously described [40,41]. The decrease in absorbance at 540 nm was
monitored in a standard swelling buffer (215 mM mannitol, 50 mM sucrose,
10 mM KCl, 3 mM KH2PO4, 0.5 mM MgCl2, 10 mM HEPES pH 7.4, 5 mM
succinate, 2 μM rotenone and 1 μg/ml oligomycin) and in the buffer used for DA
accumulation experiments. Ca2+ (100 μM) and DA (2×10−7 to 5×10−5 M)
were added 2 and 5 min after the addition of intact mitochondria, respectively.
2.7. Mitochondrial enzyme activities
NADH CoQ reductase (complex I) activity was assayed in disrupted
mitochondrial (0.2 mg protein/ml) at 25 °C in 20 mM potassium-phosphate
buffer pH 7.2. Containing 5 mM MgCl2 and 1 mM KCN. The reaction was
started by the addition of 0.14 mM NADH and 50 μM of ubiquinone-5;2,3-
dimethoxy-5-methyl-6-[3-methyl-2-butenyl]-1,4-benzoquinone (CoQ1) in the
presence or absence of rotenone (10 μM). The decrease in NADH absorbance
was followed at 340 nm for 1 min with a 3-s interval between successive
readings and 1 sec initial delay [42,43]. The residual activity of complex I was
less than 2–4% in rat brain mitochondria and 10–15% in platelet mitochondria.
Succinate CoQ oxidoreductase (complex II) activity was assayed in
disrupted mitochondria (0.1 mg protein/ml) at 25 °C, in 50 mM potassium-
phosphate buffer pH 7.4 containing 0.05 mM K EDTA and 1 mM KCN. The
reaction was started by the addition of 50 μM CoQ1 and 0.06 mM 2,6-
Dichloroindophenol sodium salt hydrate (DCIP) with or without 20 mM K-
succinate. Activity was assayed by following the decrease in the absorbance of
DCIP at 600 nm as previously described [44].
Cytochrome c oxidase (complex IV) activity was assayed in mitochondrial
preparation (0.1 mg protein/ml) at 25 °C in 40 mM potassium-phosphate buffer
pH 6.2. The reaction was started by the addition of reduced cytochrome c (final
concentration 0.12 mg/ml). Activity was assayed by following the decrease in
absorbance of reduced cytochrome c at 550 nm [45].
2.8. Dopamine accumulation in intact mitochondria
Intact mitochondria (1 mg protein) were preincubated at 30 °C for 5 min in
10 mM HEPES pH 7.4 buffer containing 195 mM mannitol, 65 mM sucrose,5 mM KCl, 1 mM MgCl2, 1 mM KH2PO4, 5–100 mM NaCl, 0.2 mM
tranylcypromine and 0.2 mM ATP or 5 mM potassium succinate. 10–400 nM
[3H]-dopamine (24.01 ci/mmol NEN, Boston, MA) was added in the presence or
absence of 10−4 M of cold DA and incubated for an additional 2 min at the
initial, linear rate of the reaction. Incubation was terminated by rapid filtration
through GF/B filters followed by three washes with ice-cold buffer. Dried filters
were counted for tritium content in liquid β-scintillation counter (1409
WALLAC, Finland). Pharmacological specification of the accumulation of
50 nM 3[H]-dopamine was studied in the presence of 11 different concentrations
of various drugs (10−7 to 10−3 M) which were pre-incubated with intact
mitochondria for 5 min. The solutions, which were used to dissolve the drugs,
were added to control mitochondria.
The accumulation of DA into intact mitochondria was also measured by
HPLC. The reaction was terminated by centrifugation at 12,000×g for 10 min
at 4 °C and processed as described above for the measurement of intracellular
DA.
2.9. Subjects
A total of 77 inpatients and 24 control subjects participated in the study. All
patients met DSM-IV criteria for schizophrenia (acute exacerbation), bipolar
disorder (BD) depressed type or recurrent major depression (MDD). Consensus
diagnosis by two senior psychiatrists was based on extended clinical interview
and patients' chart review. Patients with schizoaffective illness were excluded.
Twenty-four subjects without prior psychiatric history served as a control group.
This group was age and sex matched to the schizophrenic group. Table 1
displays some of the demographic characteristics of the study groups. All
schizophrenic patients (n=50) were in a state of acute psychotic exacerbation.
At the time of blood sampling 25 were medication-free for at least 1 month and
most patients had not received medication for significantly longer periods. Upon
admission some short acting benzodiazepine was used when necessary to
control agitation and restlessness until blood was collected after which
antipsychotic treatment was started. The remaining 25 schizophrenic patients
were receiving at the time of the study various antipsychotic medications at
conventional doses including haloperidol (n=7), chlorpromazine (n=6),
perphenazine (n=4), clozapine (n=6) and resperidone (n=2). Some received
additional anticholinergic medications and benzodiazepines. MDD patients
(n=17) received an antidepressant treatment, mostly selective serotonin
reuptake inhibitors, or tricyclic antidepressants. BD patients (n=10), all
depressed at the time of the study, were on a combination of a mood stabilizer
and antidepressants. Patients who needed additional medications for other
medical conditions were excluded. All patients were given an explanation about
the purpose of the study and provided a written informed consent. The study was
approved by the Institutional Review Board.
Fig. 1. DA dissipation of Δψm in SH-SY5Y analyzed by confocal microscopy.
Cultured SH-SY5Y cells in HBSS were loaded for 15 min with 5 μM of the
fluorescent probe- JC-1 at 37 °C. Scans were taken after cells were treated with:
5 μMCCCP, 1 μM rotenone and 10−4 MDA for 5 min. (A) Representative scans
of cells control cultures and cells treated with DA or CCCP (B) Quantification of
the results of 8–10 different experiments. Data analysis was performed using
Image Pro Plus MediaCybernetics software. Results are means±SEM. The
significant difference between treatments was analyzed by ANOVA followed by
Bonferroni post-hoc test. ⁎p=0.0013, ⁎⁎p=0.025, ⁎⁎⁎p=0.032 vs. control.
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Blood (50–80 ml) was collected from the cubital vein without tourniquet
between 8 and 10 AM and mixed 9:1 with 3.8% (w/v) tri-sodium citrate.
Platelets were isolated (1–3 h after blood sampling) by centrifugation at 1000×g
for 30 min from platelet-rich plasma. Isolated platelets were immediately
washed with Tyrode's buffer pH 7.4 containing 1 mM EDTA as previously
described [46]. The platelet pellet was gently re-suspended in ice cold 10 mM
Tris buffer pH 7.4 containing 250 mM sucrose and 1 mM EDTA and disrupted
by a Dounce-A homogenizer (20–30 strokes). The breakdown of the platelets
was verified by light microscopy. The homogenate was centrifuged at 1000×g at
4 °C for 20 min to remove unbroken cells. The supernatant, containing the
cytoplasmic extract was centrifuged at 12,000×g at 4 °C for 15 min and an
enriched mitochondrial fraction was isolated on Percoll as previously described
[17,27,47]. Electron microscopy, showed a sediment of intact mitochondria with
few dense granules and α-granules. The final preparation was immediately
stored at −70 °C until use.
2.11. Data analysis
Statistical significance was determined by one way ANOVA followed by
Bonferroni post hoc multiple comparisons test. For the effect of succinate effects
paired t-test was used. SPSS 14.0 program was used for all analyses.
2.12. Chemicals
All drugs were purchased from Sigma Chemical Company St. Louis, MO,
USA. JC-1 was purchased from Molecular Probes (Eugene, USA). Media for
tissue culture was purchased from Biological Industries (Beit Haemek Ltd.,
Israel). All other materials were of the highest purity and were purchased from
standard commercial sources.
3. Results
3.1. DA mitochondria interaction in intact cells
3.1.1. DA dissipation of Δψm
Previously, we have shown that DA inhibits complex I
activity in disrupted brain mitochondria. In the present study we
investigated whether this inhibition influences mitochondrial
functionality in intact viable cells. DA effect on mitochondrial
function was studied by measuring changes in mitochondrial
membrane potential (Δψm) as a marker for the oxidative
phosphorylation system (OXPHOS) activity in living SH-SY5Y
cells. Confocal microscopy demonstrated that DA (10−4 M)
caused a significant depolarization of Δψm in cultured SH-
SY5Y loaded with JC-1. 5 μMCCCP applied for 5min was used
as a positive control (Fig. 1A). Quantification of 8–10 experi-
ments, 3–4 scans in each, demonstrated a significant depolar-
ization of Δψm by DA (30%; pb0.032). Similar effect was
observed in the presence of rotenone (32%; pb0.025) and a
more extensive depolarization was caused by CCCP (50%;
pb0.001) (Fig. 1B).
Previously it was shown that confocal microscopy should be
used with caution for measurements of Δψm kinetics due to an
uncoupling effect of the laser illumination itself [48], therefore,
DA effects on mitochondrial function in living cells were further
studied by measuring changes ofΔψm using the flow cytometry
technique. Treatment of SH-SY5Y cells with DA or rotenone,
for 5–10 min, resulted in a significant dissipation of mitochon-
drial membrane potential (20–30%; pb0.012, 70–80%; pb0.01, respectively). CCCP almost completely abolished mito-
chondrial membrane potential (95%; pb0.01) (Fig. 2). Addition
of 10−4 M cocaine, which prevents DA uptake into cells [24],
abolished DA dissipation of Δψm, suggesting that intracellular
DA is involved in this process.
DA had no effect on cell viability under our various assay
conditions.
3.1.2. DA, complex I, and dissipation of Δψm
In order to study whether DA effect on Δψm in intact cells is
mediated through complex I inhibition, we bypassed complex I
by adding succinate, which donates electrons through succinate
CoQ oxidoreductase (complex II) to CoQ of the OXPHOS.
Succinate can be taken up by the Na+-coupled carboxylate
transporters 2 and 3, which are expressed in brain neuronal and
Fig. 2. DA dissipation ofΔψm in SH-SY5Yanalyzed by FACS. Suspended SH-SY5Y cells (10
6 cells/ml HBSS or PBS) were pretreated with 5 μM of CCCP, 1 μM of
rotenone or 10−4 M of DA for 5 min, before the incubation with JC-1 at 37 °C. For succinate induced respiration, 5 mM succinate was added to cells immediately before
treatment. (A) Representative FACS scans of cells treated with DA, rotenone and CCCP with or without succinate. FL-1-H— red fluorescent aggregates, F-2-H —
green fluorescent monomers. (B) Quantification of FACS results. Quantification of the succinate FACS appears in Fig 3. Data are means±SEM of 10 experiments. The
significant difference between treatments was analyzed by ANOVA followed by Bonferroni post-hoc test ⁎pb0.001; ⁎⁎pb0.012 vs. control.
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(5×10−4 M) to dissipate Δψm was completely abolished.
Rotenone (1 μM) induced dissipation of Δψm was partially
prevented by succinate (60% depolarization as compared to
80% without succinate). Notably, succinate ability to reverse
rotenone-induced dissipation of Δψm was attenuated in the
presence of DA in a dose dependent manner (Fig. 3). Such DA
induced attenuation was not observed in the presence of 10 μM
rotenone. Further support for the inability of DA to inhibit
complex II was demonstrated by the lack of effect of 5×10−4 M
DA on complex II activity in disrupted mitochondrial prep-
aration (Table 2), as opposed to its ability to inhibit complex I
activity (data not shown, [24]).
3.1.3. ROS Formation in the presence of DA
To determine whether ROS formation is involved in DA
induced dissipation of Δψm we analyzed superoxide and H2O2
production using 5 μM MitoSOX and 25 μM H2DCFDA,
respectively, in SH-SY5Y cells treated with 10−4 and 10−6 M
DA for up to 30 min. During this time interval no significant
increase in ROS production was observed in the presence of
DA. On the contrary, a significant reduction in ROS formationas detected by MitoSOX and H2DCFDA was observed in cells
treated with 10−4 M DA with no change in the presence of
10−6 M DA. The latter unexpected results call for further
studies. An increase in ROS production was observed in the
presence of 10 μM rotenone or 10−4 MH2O2 serving as positive
controls for superoxide and H2O2 production (Table 3).
3.1.4. Intracellular DA concentration
To ensure that intracellular concentrations of DA are
increased under our various assay conditions, DAwas analyzed
by HPLC. Basal levels of DA, in cells suspended in 1 ml serum
free medium and treated with 0.1 mM tranylcypromine was
0.13±0.04 pmol/106 cells. Following incubation with 10−4 M
DA for 10 min, intracellular DA levels increased to 15.6±
0.7 pmol/106 cells (pb0.001), indicating that about 0.1% of the
extracellular dopamine was taken-up by 106 cells. Succinate
had no effect on basal as well as DA induced intracellular DA
levels. Although tranylcypromine was used to inhibit MAO, a
small amount of DOPAC was still formed in the presence of
10−4 M DA and was about 12% of DOPAC formed in the
absence of the inhibitor (1.2±0.2 vs. 10.1±1.1 pmol/106 cells,
respectively).
Table 3
DA does not induce ROS formation
Drugs Superoxides production
(% of Control)
H2O2 production
(% of Control)
Control 100.0±1.1 100.0±1.8
DA 10−4 M 85.0±1.1c 89.6±3.3b
DA 10−6 M 108.2±1.3 94.1±1.5
Rotenone (10 μM) 110.7±1.6a –
H2O2 10
−4 M – 112.0±1.3c
The effect of DA on the formation of superoxides and ROS (specifically H2O2)
was measured loading cell with MitoSOX and H2DCFDA, respectively as
described in Materials and methods. Data represent results of loaded cells
incubated with the different drugs for 30 min. Data are means±SEM of 4–6
experiments. The significance of the difference (df=3 F=31.1 pb0.0001 for
superoxide; df=3 F=23.3 p=0.0001 for ROS) was analyzed by one-way
ANOVA followed by Bonferroni post-hoc test. apb0.031; bpb0.0094;
cpb0.003 vs. the control.
Fig. 3. Succinate overcomes DA induced dissipation of Δψm in the presence or
absence of rotenone analyzed by FACS. In order to bypass the electron transport via
complex I, suspended SH-SY5Y cells (106 cells/ml) were treated with succinate
(5 mM), the complex II substrate, in the presence or absence of 10−4 M and
5×10−4M of DA and/or 1 μMof rotenone for 5min, before the incubationwith JC-
1 at 37 °C. (A) Succinate. (B) Rotenone. (C) Succinate+rotenone. (D) DA 10−4 M;
(E) Succinate+DA10−4M. (F)Rotenone+succinate+DA10−4M. (G)Rotenone+
succinate+DA 5×10−4 M. Data are means±SEM of 12 experiments. The
significant difference induced by succinate was analyzed by paired t-test ⁎pb0.0069
(C) vs. (B); ⁎⁎pb0.003 (E) vs. (D); +pb0.043 (F) vs. (C); ++pb0.029 (G) vs. (C).
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3.2.1. Integrity and purity of isolated mitochondria
Integrity and purity of the isolated mitochondria were
evaluated by electron microscopy, which showed that 95–
98% of the preparation consisted of mitochondria with an intact
outer membrane. No synaptic vesicles/synaptosomes were ob-
served. Membrane integrity of mitochondria was further dem-
onstrated by their inability to metabolize NADH in the presence
of CoQ or ferricyanide. Purity of preparation was further
established by the determination of cytochrome c oxidase and
NADH CoQ1 reductase activities. Cytochrome c oxidase
activity in our preparation was 4.58±0.51 μmol/mg protein/
min, which is similar to its previously reported activity in non-
synaptosomal mitochondria isolated from rat brain [38]. NADH
CoQ reductase activity in disrupted mitochondrial preparation
was highly sensitive to rotenone inhibition with a residual
activity of less than 3%. Functional metabolic integrity of the
mitochondrial preparation was assessed by measurement of its
respiratory activity, which resulted in respiratory control ratio of
6.5±0.5 (mean±SEM; n=5) in standard respiration buffer and
of 6.9±0.4 (mean±SEM; n=5) in the buffer used for DA
uptake experiments. Moreover, swelling of mitochondria in aTable 2
DA does not inhibit succinate CoQ oxidoreductase activity
Succinate CoQ oxidoreductase
(μmol/mg protein/min)
Control (without succinate) 0.0053±0.0023
Control (with succinate) 0.0202±0.0014
DA (with succinate) 0.0211±0.0005
Effects of 5×10−4 M DA on succinate CoQ oxidoreductase activity were
measured in the presence of 20 mM succinate in disrupted rat brain
mitochondria. Data are means±SEM of 3 experiments.standard swelling buffer and in the uptake buffer demonstrated
similar results. Thus, the decrease in absorbance at 540 nM
during 10 min without any additions was negligible and similar
in both buffers. The addition of Ca2+ (100 μM) induced a
significant decrease in optical density of 0.125±0.011 and
0.133±0.017 (mean±SEM n=7) during 8 min for standard
swelling buffer and uptake buffer, respectively. DA (2×10−7 toFig. 4. The saturation and time dependent curves of dopamine accumulation in
intact mitochondria. (A). The accumulation of 3[H]-dopamine (10–400 nM)
during 2 min of incubation at 30 °C by intact mitochondria (1 mg protein) was
determined in the presence or absence of unlabelled dopamine (10−4 M). Data
are means±SEM of triplicates of the specific accumulation from 6 experiments
in which succinate was used as a respiratory substrate. (B). Time dependent
accumulation of dopamine in intact mitochondria. Following 5 min of pre-
incubation, intact mitochondria were incubated for 1–15 min at 30 °C and the
accumulation of 50 nM 3[H]-dopamine in the presence or absence of cold
dopamine (10−4 M) was determined. Dopamine accumulation reached 50% of
its maximum within 4 min. Data are means±SEM of triplicates of the specific
accumulation from 3 experiments.
Table 4
The effect of various drugs on dopamine accumulation by intact rat brain
mitochondria
Compound IC50 (M)
NE 1.1×10−4
MPP+ 1.5×10−5
5HT N10−2
Spermine N10−2
Nomifensine N2.5×10−3
GBR-12909 N10−3
Cocaine N2×10−3
Desipramine N2×10−3
Reserpine N10−2
SCH-23390 N10−2
Sulpiride N10−2
SKF-38393 N10−2
Quinpirole N10−2
The specific uptake of 3[H]-dopamine (50 nM) by intact mitochondria was
determined in the presence of eleven different concentrations (10−3 to 10−7 M)
of the various drugs. Data are the results of triplicate determinations from 4
experiments for each drug.
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affect Ca2+ induced swelling in both buffers.
3.2.2. Characteristics of dopamine accumulation by
mitochondria
3[H]-dopamine was taken up by intact mitochondria in a
saturable (Fig. 4A) and time dependent (Fig. 4B) manner with
kinetic constants derived from Lineweaver–Burk plots of
apparent Km=122.0±28.6 nM and Vmax=1.41±0.15 pmol/mg
protein/min. Assuming 1 μl matrix volume/mg mitochondrial
protein [50], the calculated internal DA concentration for a
typical uptake experiment (50 nM DA; 2 min incubation) was
2.56±0.04 μM, thus representing a concentration gradient of
about 50-fold.
In order to ensure that DA, rather than one of its metabolites,
was taken up by mitochondria, DA accumulation was measured
by HPLC. Fig. 5 shows that dopamine per se is taken up by
intact mitochondria. Moreover, in the absence of tranylcypro-
mine, a non-selective MAO A and B inhibitor, DA accumula-
tion is significantly reduced (pb0.001), probably due to its
enzymatic metabolism (Fig. 5 column B), further supporting
that DA, and not its MAO metabolites, was taken up by the
mitochondria.
DA accumulation by intact mitochondria was Na+ depen-
dent, and substitution of Na+ with Li+ almost abolished DA
uptake (Fig. 5). Studying three additional concentrations of Na+
indicated a bell shape dependency. Thus, at low 5 mM and high
100 mM concentrations of Na+, no accumulation of DA was
observed, and at 20 mM of Na+, DA accumulation was 45±Fig. 5. The dependence of dopamine accumulation in intact mitochondria on
Na+, energy and membrane potential. Accumulation of dopamine (50 nM) in the
presence of different drugs by intact mitochondria was determined by HPLC
with an electrochemical detector. Incubation was performed as described for the
accumulation of 3[H]-dopamine, but the reaction was terminated by centrifu-
gation at 15,000×g at 4 °C for 15 min. The pellet was washed three times with an
excess of ice-cold buffer with in-between centrifugation. The mitochondria in
the final pellets were disrupted by 0.1 M HClO4 and by freezing and thawing.
The supernatant was separated by centrifugation and was analyzed by HPLC.
(A) Uptake under control conditions (B) in the absence of the MAO inhibitor
tranylcypromine (C) in the presence of 50 mMLiCl instead of 50 mMNa+ (D) in
the absence of succinate and (E) in the presence of 5 μM of the uncoupler
carbonylcyanide m-chlorophenyl-hydrazine (CCCP). Data are means±SEM of
triplicates from 4 experiments. The significant difference between treatments
was analyzed by ANOVA followed by Bonferroni post-hoc test. ⁎pb0.001 for
all treatments vs. control.7.5% (mean±SEM n=4) of that observed at 50 mM Na+. Na+
dependent DA accumulation by intact mitochondria took place
following the addition of either ATP or succinate. In the absence
of both external energy sources, DA accumulation was almost
completely abolished. Finally, disruption of mitochondrial
membrane potential by the addition of 5 μM of the uncoupler
carbonyl cyanide m-chlorophenylhydrazine (CCCP) also pre-
vented the accumulation of DA (Fig. 5).
3.3. DA accumulation in the presence of various drugs
The effect of various DA-related drugs on DA accumulation
by mitochondria is shown in Table 4. 1-methyl-4-phenylpridi-
num (MPP+) and norepinephrine (NE) inhibited DA accumu-
lation with IC50 of 15.3±0.4 μM and 112±5 μM, respectively
(Fig. 6A and B). Inhibition by MPP+ and NE showed a simple
noncompetitive inhibition pattern (Fig. 6C and D). Other
amines such as serotonin (5-HT) and spermine did not affect
DA uptake (Table 3). Moreover, 3[H]-5HT, which has an indol
group instead of a catechol, was not accumulated by intact
mitochondria (data not shown). In addition, DA accumulation
was not inhibited by GBR-12909 and nomifensin (inhibitors of
DA plasma membrane transporter-DAT) or by reserpine
(inhibitor of the vesicular monoamine transporter-VMAT).
Nor was DA accumulation inhibited by cocaine or desipramine
(inhibitors of monoamines and NE plasma membrane transpor-
ters, respectively). DA D1 and D2 receptors agonists (SKF-
38393 and quinipirole) or antagonists (SCH-23390 and
sulpiride) did not inhibit DA accumulation, suggesting that
DA does not bind to a known DA-binding site.
3.4. Increased susceptibility of complex I activity to DA
inhibition in platelets of schizophrenic patients
The relevance of DA complex I interaction to schizophrenia
was verified in mitochondria isolated from platelets of schizo-
phrenic patients and control subjects. Similar to previous reports,
Fig. 6. Inhibition of 3[H]-dopamine accumulation in intact mitochondria byMPP+ and norepinephrine. Intact mitochondria were pre-incubated with the 10−7 to 10−3 M
MPP+ (A) and norepinephrine (B) for 5 min before the addition of 50 nM 3[H]-dopamine. Data are means±SEM of triplicates from 6 experiments. Double reciprocal
Lineweaver–Burk analysis was performed on the inhibition curves for MPP+ (C) and Norepinephrine (D). 3[H]-dopamine (10–250 nM) accumulation experiments in
the presence of different concentrations of the inhibitors were performed. Data are means of triplicates from a representative experiment replicated 4 times.
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patients at acute psychosis regardless whether they were
medicated or not, as compared with control subjects [16].
Addition of 10−5 M DA resulted in a significant inhibition of
complex I activity both in patients and in normal subjects.
However, in schizophrenic patients inhibition of mitochondrial
complex I was twice as much as in control subjects (69.7% vs.
38.6%). Patients with affective disorders did not differ from the
controls (Table 5).Table 5
The degree of dopamine inhibition of mitochondrial complex I activity in
platelets of schizophrenic patients
Subjects Complex I activity
(% of control)
Dopamine
inhibition (%)
Controls (n=24) 100.0±40.2 38.6±13.4
Medicated schizophrenics (n=25) 242.3±64.4⁎ 69.1±19.9⁎
Unmedicated schizophrenics (n=25) 225.1±41.5⁎ 72.6±15.0⁎
Recurrent major depression (n=17) 103.3±34.1 31.7±16.5
Bipolar disorder (depressed type, n=10) 104.50±44.7 34.5±13.6
Complex I activity (NADH CoQ reductase) was measured as described in
Materials and methods. In control subjects rotenone sensitive complex I activity
is 131.87±53.1 nmol/mg protein/min. Values are means±SD. Results were
analyzed by ANOVA followed by Bonferroni post hoc test. ⁎pb0.001 vs.
controls and vs. both groups of patients with affective disorder.4. Discussion
The present study provides evidence for DA ability to affect
mitochondrial function, possibly through its interactions with
complex I. This DA-mitochondria interaction was not associ-
ated with cell death, suggesting it as a preferable mechanism for
DA deleterious effects in non-degenerative DA-disorders such
as schizophrenia. Mitochondrial membrane potential (Δψm)
was used as a marker for the OXPHOS activity in human
neuroblastoma SH-SY5Y cells. Both confocal microscopy and
FACS results show a significant dissipation (25–30%) of Δψm
by DA already after 5 min of treatment with no effect on cell
survival. These findings are in line with a previous report on DA
induced reduction of mitochondrial membrane potential in EBV
transformed B lymphocytes [51]. DA induced dissipation of
Δψm was prevented in the presence of cocaine, which inhibits
the uptake of DA both by DA and NE plasma membrane
transporters, suggesting that DA-induced mitochondrial dys-
function depends on DA uptake into the cells.
Microdyalisis studies report that extracellular DA concentra-
tions can range between 3 and 750 nM depending on neuronal
activation and brain region[52,53]. Synaptic concentrations of
DA can range between 30 and 100 mM following activation of
DA cell bodies [54]. In SH-SY5Y cells as well as in isolated
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range used in this study (5×10−5 to 10−4 M). At such con-
centrations exposure of cells to DA for 12–18 h does not affect
cell viability or causes apoptosis [24,39,55]. Under pathological
condition, which are associated with massive release of DA, as
in schizophrenia [7], mitochondria enriched nerve terminals are
exposed to increased DA levels due to its increased re-uptake
and synthesis [56]. Therefore, to investigate DA effects on
mitochondria, cells were exposed to 100 μM DA for up to
10 min. In addition, to prevent DA metabolism to DOPAC and
the production of H2O2, which can lead to a state of oxidative
stress, MAO A and B inhibitor was used throughout the study.
To study the involvement of complex I in DA-induced
alterations of Δψm the OXPHOS was activated through
complex II, thereby bypassing complex I. Succinate, a complex
II substrate, completely abolished DA-induced dissipation of
Δψm, suggesting that DA affect Δψm by inhibiting the
OXPHOS prior to complex II, namely complex I. One may
argue that succinate successfully reversed DA inhibition of
complex II. If so, it is anticipated that the ability of succinate to
reverse rotenone induced dissipation ofΔψm through complex I
inhibition, will not be affected by DA. However, in the present
study DA-attenuated succinate ability to reverse rotenone
(1 μM) induced dissipation of Δψm, suggesting that DA
inhibits complex I. Our previous findings suggest that DA
inhibits complex I at a site located between the binding site for
NADH and the iron–sulphour cluster N1 [24], while rotenone
inhibits electron efflux from complex I through the ubiquinone
docking site(s) on the downstream portion of the complex [57].
Further support for the involvement of complex I in DA induced
inhibition of Δψm, is the inability of DA to inhibit complex II
activity, shown in the present study, as well as that of complexes
IV and V [24], as opposed to its inhibitory effect on complex I
[24] in disrupted mitochondrial preparation. Although other
sites of interaction between DA and mitochondria, prior to
complex I, cannot be ruled-out, based on our previous and the
present results, it is tempting to hypothesis that DA ability to
inhibit complex I, which is a major determinant of mitochon-
drial respiration [58], can lead to mitochondrial dysfunction.
Interestingly, our previous findings in SH-SY5Y demonstrated
a dose-dependent decrease in ATP production, which negatively
correlated with intracellular increase in DA levels [24].
Numerous studies have claimed that DA deleterious effects
on mitochondrial function are primarily due to its catabolism by
MAO to H2O2 and oxygen free radicals, or due to its auto-
oxidation to reactive quinones [59,60]. In this study however,
exposure of cells for up to 30 min was not associated with ROS
formation including H2O2 and superoxides. These results are
not totally unexpected as cells were pretreated with the MAO A
and B inhibitor, tranylcypromine significantly reducing the
formation of DOPAC and therefore also the formation of H2O2.
In addition, HPLC results show that under our assay conditions
0.3 μM DOPAC was formed in cells exposed to the highest DA
concentration, indicating that intracellular levels of H2O2 were
elevated by 0.3 μM at most. It was previously reported that
physiological concentrations of H2O2 are in the range of 25–
60 μM and that exposing cells to 100 μMH2O2 for at least 1.5 his needed in order to induce alterations in Δψm [61]. Therefore,
the observed alterations in Δψm induced by the brief exposure
of cells to DA in our experiments cannot be linked to H2O2
formation. It is well established that inhibition of complex I can
induce the production of superoxides. It was previously sug-
gested that the site of rapid superoxide generation by complex I
is in the region of the ubisemiquinone-binding sites and not
upstream at the flavin or low potential Fe–S centers [62]. Our
previous results suggest that DA inhibits complex I between the
binding site for NADH and cluster N1 [24] and therefore a
detectable production of superoxide, is not likely to occur. In
line with the latter are the findings that Ca2+, which inactivates
complex I and inhibits electron transport upstream of the
primary site(s) of free radical production, limits the production
of superoxides in submitochondrial particles [63]. However,
other studies suggest that superoxide generation is increased in
the inactive slowly oxido-reduction activated D form of the
enzyme and therefore do not support the aforementioned study
[64]. In addition, recent reports have shown that superoxides
can be generated at the tightly bound FMN [65,66], which
maybe located upstream to the proposed DA binding site.
Nevertheless, under our experimental conditions we could not
detect superoxide formation in the presence of DA, suggesting
that either superoxides were not generated in association with
DA inhibition, or that in the presence of DA superoxides were
detoxified by mitochondrial or cellular protective mechanisms.
To overcome the formation of reactive quinones cells were
suspended in HBSS solution pH 7.4 that limits oxidation. In
addition, cells were treated with DA for 10–15 min, while
previous findings demonstrated that more than 2 h were needed
for a sufficient build-up of the damaging quinones to produce
inactivation of OXPHOS in cells [28]. These findings are in
favor of a direct interaction between DA and complex I, leading
to the dissipation of Δψm.
In order to be able to inhibit complex I activity in intact
mitochondria, DA has to cross the mitochondrial highly selec-
tive inner membrane. Indeed, HPLC studies demonstrate that
DA can be accumulated by synaptosomal-free, intact, coupled
and respiring mitochondria. The accumulation of exogenous
3[H]-DA by mitochondria fulfilled several criteria for a
transporter mediated process. DA accumulation by mitochon-
dria was rapid and reached 50% of its maximum within 4 min. It
showed saturability with an apparent Km of 122.0±28.6 nM,
similar to that of striatal DAT [67] and Vmax of 1.41±0.15 pmol/
mg protein/min, similar to that of DAT in cerebral cortex,
hypothalamus, midbrain, medulla oblongata and cerebellum
[68]. A concentration gradient for DA of about 50-fold was
formed, assuming 1 μl matrix volume per mg mitochondrial
protein [50]. Accordingly, 2.56±0.04 μM DA can be accu-
mulated in the mitochondria following their exposure to 50 nM
of DA for 2 min, which is far less than the concentration range at
nerve endings following release and reuptake of DA, and
therefore in the range of the concentration of DA needed for
complex I inhibition [24].
DA accumulation was an energy-dependent process. The
kinetics of DA accumulation was similar when energy for the
process was available either by substrate (succinate) oxidation
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absence of succinate (data not shown). In the presence of an
uncoupler CCCP DA was not taken up, further supporting its
uptake dependence on coupled functioning mitochondria. DA
accumulation by mitochondria was dependent on sodium con-
centrations in a bell shape dependent manner. A possible ex-
planation for such a curve is that at high intracellular Na+
concentrations mitochondrial Ca+2 efflux can be increased,
leading to inhibition of mitochondrial respiration and to a re-
duction in ATP production [69] and consequently to a decrease
in DA uptake. The mechanism by which intracellular Na+
enables DA accumulation in the mitochondria is still unclear.
We suggest that mitochondrial Na+ gradient, which is kept by
the mitochondrial Na+/H+ exchanger, can serve as a driving
force for this process [70–73]. The involvement of directly or
indirectly Na+ dependent mitochondrial ion transporters such as
the Na+/H+, Na+/Ca+2 and H+/Ca+2 exchangers and H+
symporter [74,75] in DA uptake is currently under investiga-
tion. It is well documented that the resting cytosol concentration
of Na+ is 5–10 mM, whereas DA accumulation by the mito-
chondria was considerable at 20 mM Na+ and increased at
50 mM Na+. However, during synaptic activation, powerful
fluorescent indicators sensitive to cytosolic concentrations of
Na+, revealed measurable changes in [Na+]i (5–10 folds). Such
changes in [Na+]i were observed during synaptic activation of
glutamate receptors in midbrain DA neurons and Purkinje cells
[76–79] as well as during hyperpolarization of hippocampal
pyramidal cells and DA cells in the substantia nigra pars
compacta [50,80]. These observations suggest that mitochon-
dria can be exposed to significant fluctuations in intracellular
[Na+], which under certain conditions, such as synaptic
activation, can induce Na+ dependent mitochondrial DA accu-
mulation. In our cellular model DA induced 20–30% dissi-
pation in Δψm possibly via interaction with complex I. An
attractive possibility is that physiological fluctuations in
intracellular [Na+] enable DA accumulation in mitochondria.
Further studies on the role intracellular [Na+] plays in DA
induced alteration of mitochondrial function are currently
underway.
The characteristics of mitochondrial DA accumulation
described above is not compatible with the idea of DA binding
to a mitochondrial membrane-binding site, as was previously
suggested [81]. This notion is further supported by the inability
of DA D1 and D2 agonists and antagonist to inhibit mito-
chondrial DA accumulation. DA uptake is unlikely due to its
positive charge, since two other amines, 5-HT and spermine
were not taken-up by mitochondria and did not inhibit DA
uptake, respectively. Mitochondrial DA accumulation is also
probably not due to its interaction with MAO, since in the
absence of a MAO inhibitor DA accumulation was attenuated,
and since 5-HT was unable to compete with DA.
The pharmacological profile of DA accumulation by
mitochondria differed from that of DAT (Na+ gradient linked
transporter) and that of VMAT (H+ gradient linked transporter).
Neither DAT specific inhibitors (GBR-12909 and nomifensine),
nor a VMAT specific inhibitor (reserpine), affected mitochon-
drial DA accumulation. Interestingly, MPP+, which is accumu-lated by mitochondria and inhibits complex I activity with an
IC50=700 μM [50,57], inhibited DA accumulation by mito-
chondria with a Ki of 15.3±0.4 μM in a non-competitive
manner. The noncompetitive inhibition of DA uptake by MPP+
suggests that DA uptake depends on mitochondrial membrane
potential, similar to previous findings on mitochondrial uptake
of other positively charged molecules such as polyamines [82].
Norepinephrine, which efficiently competes with DA on the
VMAT [16,83,84] and less so on the DAT [17,19,85–87], also
inhibited mitochondrial DA accumulation in a noncompetitive
manner but was 10 times less efficient than MPP+. These results
suggest that under certain conditions, such as increased intra-
cellular sodium concentrations or extensive DA transmission,
an active process of DA uptake by mitochondria, which is
distinct from that of both DAT and VMAT, can take place.
The results hitherto suggest that under pathological states
associated with increased [Na+]i due to synaptic activation,
abnormal DA transmission and/or dysfunction of MAO, an
interaction between DA and mitochondrial complex I could be
part of the pathogenesis. Such abnormalities have been reported
in schizophrenia [88–93]. In line with the latter, in the present
study we showed a pathological interaction between DA and
complex I in schizophrenia. The data show that 10−5 M DA
inhibited complex I activity in schizophrenic patients twice as
much as in control subjects, in disrupted mitochondria isolated
from platelets. This finding further suggests that DAmodulation
of complex I activity is abnormal in this DA-related patho-
logical condition. The interaction between DA and complex I
and whether it contributes to the pathology of schizophrenia is
still unclear, since complex I activity in schizophrenic patients is
disease state dependent, increased in patients with positive
symptomatology and decreased in those with residual schizo-
phrenia [16,94]. However, one cannot exclude the possibility
that the increased inhibition of complex I by DA could be an
endogenous means to compensate for the increase in complex I
activity in schizophrenia. Alternatively, the higher exposure to
DA in patients, may lead to the increased complex I activity to
balance the enhanced DA inhibitory effect (for a more detailed
discussion on the interaction between DA and complex I see
Ben-Shachar 2002). Interestingly, in a previous study it was
demonstrated that the extent of DA induced reduction in Δψm
was similar in EBV transformed lymphocytes of schizophrenic
patient and controls [51]. One explanation for these findings can
be the higher susceptibility of complex I to DA in patient in
whom an increased complex I activity was reported.
The validity of peripheral abnormalities as proxies for
measuring brain dysfunction has been questioned. Mitochon-
dria are partly independent organelles, contain their own DNA
and their OXPHOS is highly preserved along evolution and in
different tissues. Biochemical and pharmacological similarities
have been observed between blood platelets and 5HT or DA
containing neurons of the CNS [95]. Numerous studies have
shown that platelets from schizophrenic patients behave dif-
ferently than those isolated from healthy controls in dopamine
uptake, 5-HT content arachidonic acid metabolism, inositol
phosphate levels and disturbance of calcium homeostasis [95–
97]. In addition, a reduction in imipramine binding was found
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patients and patients who committed suicide [98]. In patients
with Parkinson's or Alzheimer's diseases, a correlation has been
demonstrated between platelet and postmortem brains for the
reduction in mitochondrial complex I and cytochrome c oxidase
activities, respectively [99,100]. The aforementioned substanti-
ate the supposition that alterations in peripheral mitochondrial
complex I abnormalities may be reflected in brain. Indeed,
abnormalities in the OXPHOSwere observed both in blood cells
and in postmortem brain specimens [29,88,101,102].
Together with the previously mentioned inhibitory effect of
DA on complex I activity, the findings in schizophrenic patients
may indicate that in addition to DA receptors, complex I is a
potential target for DA. In this connection it is notable that
mitochondria are target organelles for DA by the virtue of the
fact that MAO, the main metabolizing enzyme of DA, is located
on their outer membrane. Under normal conditions MAO is
probably protecting the mitochondria from the vicious effects of
DA.
In view of the ability of DA to impair cell energy metab-
olism, or to cause cell death by forming highly reactive oxygen
species, it is tempting to hypothesize that DA may affect mito-
chondria in a dual manner depending on the intracellular state.
Consequently, we suggest that DA induced oxidative mecha-
nism is more likely associated with neurodegenerative DA
disorders such as Parkinson's disease, while a mechanism
involving an interaction between DA and complex I, can better
explain the pathology of non-degenerative DA disorders such as
schizophrenia. Interference with mitochondrial function can
effect normal neuronal transmission, which may impair optimal
functioning of critical circuits necessary for normal cognitive,
emotional and behavioral functions.
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